[email protected]
Kathrin Jansen
Head of Vaccine Research & Development at Pfizer; Leading Scientist in COVID-19 Vaccine Effort
Kathrin U. Jansen, PhD, is Senior Vice President and Head of Vaccine Research and Development at Pfizer Inc, and a member of Pfizer’s Worldwide Research and Development leadership team. Dr. Jansen oversees a fully integrated, global vaccines research and development organization, with responsibilities ranging from discovery to registration and post-marketing commitments of first-in-class or best-in-class vaccines to prevent or treat diseases of significant unmet medical need. More recent accomplishments are the global licensures of Prev(e)nar13® to prevent pneumococcal diseases and the development and licensure of Trumenba®, the first vaccine licensed in the United States to prevent invasive disease caused by Neisseria meningitidis serogroup B.
Dr. Jansen received her doctoral degree in microbiology, biochemistry & genetics from Phillips Universitaet, Marburg, Germany. Following completion of her formal training, she continued her postdoctoral training at Cornell University working on the structure and function of the acetylcholine receptor. She then joined the Glaxo Institute for Molecular Biology in Geneva, Switzerland, where she focused on basic studies of a receptor believed to be a drug target to treat allergies. Dr. Jansen was appointed an Adjunct Professor at the University of Pennsylvania – School of Medicine in 2010. Before the Wyeth acquisition by Pfizer in 2009, Dr. Jansen served as Senior Vice President at Wyeth Pharmaceuticals and on Wyeth’s Research and Development Executive Committee since 2006 and was responsible for vaccine discovery, early development and clinical testing operations.
Dr. Jansen also briefly worked at Vaxgen as Chief Scientific Officer and Senior Vice President for Research and Development with responsibility for the company’s late stage development programs. Prior to joining Vaxgen, Dr. Jansen spent 12 years at Merck Research Laboratories where she directed or supported a number of vaccine efforts, including Merck’s novel bacterial vaccine programs and viral vaccine programs (rotavirus, zoster and mumps, measles and rubella). Dr. Jansen initiated and led the development of Gardasil®, the world’s first cervical cancer vaccine.
Videos
News
Related Speakers View all
![]() |
Hanneke Schuitemaker
Virologist, Global Head of Viral Vaccine Discovery &...
|
![]() |
Dr. Joel Selanikio
Award-Winning Physician, Health & Technology Activis...
|
![]() |
Dr. Anthony Fauci
Director of the National Institute of Allergy and In...
|
![]() |
Owais Durrani
Emergency Medicine Physician
|
![]() |
Barney Graham, M.D., Ph.D
Immunologist, Virologist & Deputy Director of the Va...
|
![]() |
Kizzmekia Corbett
Viral Immunologist; Lead Scientist on the Moderna Co...
|
![]() |
Cindy Eckert
Founder & CEO of The Pink Ceiling and Sprout Pharmac...
|
![]() |
Omar Lateef
President & CEO at Rush University Medical Center; Q...
|
![]() |
Zhong Nanshan
Chinese Epidemiologist & Pulmonologist
|
![]() |
Hamilton Bennett
Senior Director of Vaccine Access & Partnerships at ...
|
![]() |
Alexandra Whittington
Global Futurist, Author, Speaker
|
![]() |
Ian Frazer
Immunologist; Co-Creator of HPV Vaccine; Founding CE...
|
![]() |
Angela Hwang
Group President of Pfizer Biopharmaceuticals Group
|
![]() |
Lygeia Ricciardi
Digital Health & Patient Engagement Expert
|
![]() |
Craig H. Lipset
Former Head of Clinical Innovation at Pfizer
|
![]() |
Hasini Jayatilaka
Postdoctoral Researcher at Stanford University
|
![]() |
Tisha Rowe
Family Medicine Physician & Entrepreneur
|
![]() |
Susan Silbermann
Board of Director at HilleVax; Former Global Preside...
|
![]() |
Amy Cappellanti-Wolf
Chief Human Resources Officer at Cohesity
|
![]() |
Rachel Haurwitz
President & CEO of Caribou Biosciences, Inc.
|